Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.

Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T, Jones N, Holm S, Nyman P, Mörse H, Öberg A, Weiler-Wichtl L, Leiss U, Haberler C, Schmook MT, Mayr L, Dieckmann K, Kool M, Gojo J, Azizi AA, André N, Kieran M, Slavc I.

Open source

DOI: 10.1001/jamaoncol.2023.4437
Published: 2023-12-01
Container: JAMA Oncol
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamaoncol.2023.4437,
  title = {Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.},
  author = {Peyrl A and  Chocholous M and  Sabel M and  Lassaletta A and  Sterba J and  Leblond P and  Nysom K and  Torsvik I and  Chi SN and  Perwein T and  Jones N and  Holm S and  Nyman P and  Mörse H and  Öberg A and  Weiler-Wichtl L and  Leiss U and  Haberler C and  Schmook MT and  Mayr L and  Dieckmann K and  Kool M and  Gojo J and  Azizi AA and  André N and  Kieran M and  Slavc I.},
  year = {2023},
  journal = {JAMA Oncol},
  doi = {10.1001/jamaoncol.2023.4437},
  url = {https://doi.org/10.1001/jamaoncol.2023.4437}
}

RIS

TY  - JOUR
TI  - Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
AU  - Peyrl A
AU  -  Chocholous M
AU  -  Sabel M
AU  -  Lassaletta A
AU  -  Sterba J
AU  -  Leblond P
AU  -  Nysom K
AU  -  Torsvik I
AU  -  Chi SN
AU  -  Perwein T
AU  -  Jones N
AU  -  Holm S
AU  -  Nyman P
AU  -  Mörse H
AU  -  Öberg A
AU  -  Weiler-Wichtl L
AU  -  Leiss U
AU  -  Haberler C
AU  -  Schmook MT
AU  -  Mayr L
AU  -  Dieckmann K
AU  -  Kool M
AU  -  Gojo J
AU  -  Azizi AA
AU  -  André N
AU  -  Kieran M
AU  -  Slavc I.
PY  - 2023
JO  - JAMA Oncol
DO  - 10.1001/jamaoncol.2023.4437
UR  - https://doi.org/10.1001/jamaoncol.2023.4437
ER  -

APA

A, P., M, C., M, S., A, L., J, S., P, L., K, N., I, T., SN, C., T, P., N, J., S, H., P, N., H, M., A, Ö., L, W., U, L., C, H., MT, S., L, M., K, D., M, K., J, G., AA, A., N, A., M, K., & I., S. (2023). Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2023.4437

Source records

europe-pmc · retrieved 2026-09-26T04:21:24.918Z